Regeneron Pharmaceuticals Inc. buy EF Hutton Acquisition Co. I
Start price
23.03.23
/
50%
€736.80
Target price
23.03.24
€791.57
Performance (%)
20.86%
End price
24.03.24
€890.50
Summary
This prediction ended on 24.03.24 with a price of €890.50. The BUY prediction by EF_Hutton_Acquisitio finished with a performance of 20.86%. EF_Hutton_Acquisitio has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -0.125% | -0.125% | 28.843% | -14.947% |
| iShares Core DAX® | 3,59 % | 3,93 % | 15,38 % | 53,20 % |
| iShares Nasdaq 100 | 5,81 % | 5,52 % | 41,46 % | 91,09 % |
| iShares Nikkei 225® | 4,08 % | 8,46 % | 48,95 % | 63,93 % |
| iShares S&P 500 | 4,14 % | 4,04 % | 31,59 % | 64,84 % |
Comments by EF_Hutton_Acquisitio for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at EF Hutton Acquisition Co. I from $853.00 to $862.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat
In the thread Trading Regeneron Pharmaceuticals Inc.
Die von EF_Hutton_Acquisitio gewählte maximale Laufzeit wurde überschritten